Essential thrombocytosis is a myeloproliferative disease of unknown reason that causes progressive platelet overproduction, which this high counts of platelets appear to be associated with intravascular thrombosis and related event. There are several medications to prevent thrombosis formation in these patients, such as hydroxyurea, and aspirin. We do not have much information about the duration of the medication. Our case was a 28-year-old woman without any history of medical problem, who gave birth recently, presented to the emergency department with epigastric abdominal pain, nausea/vomiting, loss of appetite, chills and diarrhea. On initial examination, huge splenomegaly about 20 cm below the edge of the ribs in the midclavicular line were detected. All lab data were within normal ranges. Pregnancy behaves as a trigger for undiagnosed essential thrombosis in this patient. She underwent anticoagulant therapy which still continuous. It seems that pregnancy became a triggering factor for ET in our case to show up with the symptoms like thrombosis. There is lack of evidence about duration of treatment. We don’t know when we should stop the anticoagulant therapy or we should continue the medications lifelong. This issue should be considered as the basis of future studies.
| Published in | Science Journal of Clinical Medicine (Volume 10, Issue 4) |
| DOI | 10.11648/j.sjcm.20211004.21 |
| Page(s) | 143-146 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
Essential Thrombocytosis, Pregnancy, Anticoagulants, Myeloproliferative
| [1] | Epstein E, Goedel A. Hämorrhagische thrombocythämie bei vasculärer schrumpfmilz. Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin. 1934; 292 (2): 233-48. |
| [2] | Silverstein MN. Primary or hemorrhagic thrombocythemia. Archives of Internal Medicine. 1968; 122 (1): 18-22. |
| [3] | Bellucci S, Janvier M, Tobelem G, Flandrin G, Charpak Y, Berger R, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer. 1986; 58 (11): 2440-7. |
| [4] | Preston E. Primary thrombocythaemia. Lancet. 1982; 1: 1021. |
| [5] | Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine. 1995; 332 (17): 1132-7. |
| [6] | Rossi C, Randi M, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. Journal of internal medicine. 1998; 243 (7): 49-53. |
| [7] | Nissenblatt MJ, Gartenberg G, Lee ML, Sciorra LJ, Rose DV, Rajendra BR. Case Report: Essential Thrombocytosis with the Philadelphia Chromosome (Ph′). The American journal of the medical sciences. 1986; 291 (4): 276-9. |
| [8] | Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. 1981. |
| [9] | Knuutila S, Ruutu T, Partanen S, Vuopio P. Chromosome 1q+ in erythroid and granulocyte-monocyte precursors in a patient with essential thrombocythemia. Cancer Genetics and Cytogenetics. 1983; 9 (3): 245-9. |
| [10] | Mitus AJ, Schafer AI. Thrombocytosis and thrombocythemia. Hematology/oncology clinics of North America. 1990; 4 (1): 157-78. |
| [11] | Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. Journal of internal medicine. 1999; 245 (3): 295-300. |
| [12] | Mazur EM, Cohen JL, Bogart L. Growth characteristics of circulating hematopoietic progenitor cells from patients with essential thrombocythemia. 1988. |
| [13] | Murphy S, Rosenthal DS, Weinfeld A, Briere J, Faguet GB, Knospe WH, et al. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a Polycythemia Vera Study Group report. Cancer Treat Rep. 1998; 66: 1495-500. |
| [14] | Löfvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European journal of haematology. 1988; 41 (4): 375-81. |
| [15] | Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22 (1): 14-22. |
| [16] | Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A, editors. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings; 2006: Elsevier. |
| [17] | Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. Journal of Clinical Oncology. 1990; 8 (3): 556-62. |
| [18] | De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009; 94 (5): 733-7. |
| [19] | Yuan J, Wu Y, Hao J, Hu W. The comorbidity of acute ischemic stroke and splenic infarction resulting from essential thrombocythemia. Neurological Sciences. 2018; 39 (10): 1787-90. |
| [20] | Jaroch MT, Broughan TA, Hermann RE. The natural history of splenic infarction. Surgery. 1986; 100 (4): 743-50. |
| [21] | Ray S, Mridha AR, Ahammed M. Diffuse splenic infarction in a case of severe acute pancreatitis. Am J Surg. 2011; 201 (3): e23-5. |
| [22] | Tsiouris A, Cogan CM, Velanovich V. Distal pancreatectomy with or without splenectomy: comparison of postoperative outcomes and surrogates of splenic function. HPB (Oxford). 2011; 13 (10): 738-44. |
| [23] | O'KEEFE JR JH, HOLMES JR DR, Schaff HV, SHEEDY II PF, EDWARDS WD, editors. Thromboembolic splenic infarction. Mayo Clinic Proceedings; 1986: Elsevier. |
| [24] | Kim K-T, Sohn S-I, Cho K-H. Cerebral Infarct in a Patient with a History of Systemic Arterial and Venous Thrombosis from Essential Thrombocythemia. Journal of Stroke and Cerebrovascular Diseases. 2012; 21 (8): 913.e9-.e10. |
| [25] | Randi M, Fabris F, Girolami A. Thrombocytosis in young people: evaluation of 57 cases diagnosed before the age of 40. Blut. 1990; 60 (4): 233-7. |
| [26] | De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Annals of Hematology. 2009; 89 (2): 141. |
| [27] | Fang M, Agha S, Lockridge L, Lee R, Cleary JP, Mazur EM, editors. Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. Mayo Clinic Proceedings; 2001: Elsevier. |
| [28] | Oki M, Moriuchi M, Kawada H, Ogawa Y, Ando K. A case of essential thrombocythemia presenting with aortic thrombosis. The Tokai journal of experimental and clinical medicine. 2008; 33 (4): 135. |
APA Style
Behshad Pazooki, Ailar Ahangari. (2021). Essential Thrombocytosis Detected in Pregnancy: A Case Report. Science Journal of Clinical Medicine, 10(4), 143-146. https://doi.org/10.11648/j.sjcm.20211004.21
ACS Style
Behshad Pazooki; Ailar Ahangari. Essential Thrombocytosis Detected in Pregnancy: A Case Report. Sci. J. Clin. Med. 2021, 10(4), 143-146. doi: 10.11648/j.sjcm.20211004.21
AMA Style
Behshad Pazooki, Ailar Ahangari. Essential Thrombocytosis Detected in Pregnancy: A Case Report. Sci J Clin Med. 2021;10(4):143-146. doi: 10.11648/j.sjcm.20211004.21
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjcm.20211004.21,
author = {Behshad Pazooki and Ailar Ahangari},
title = {Essential Thrombocytosis Detected in Pregnancy: A Case Report},
journal = {Science Journal of Clinical Medicine},
volume = {10},
number = {4},
pages = {143-146},
doi = {10.11648/j.sjcm.20211004.21},
url = {https://doi.org/10.11648/j.sjcm.20211004.21},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20211004.21},
abstract = {Essential thrombocytosis is a myeloproliferative disease of unknown reason that causes progressive platelet overproduction, which this high counts of platelets appear to be associated with intravascular thrombosis and related event. There are several medications to prevent thrombosis formation in these patients, such as hydroxyurea, and aspirin. We do not have much information about the duration of the medication. Our case was a 28-year-old woman without any history of medical problem, who gave birth recently, presented to the emergency department with epigastric abdominal pain, nausea/vomiting, loss of appetite, chills and diarrhea. On initial examination, huge splenomegaly about 20 cm below the edge of the ribs in the midclavicular line were detected. All lab data were within normal ranges. Pregnancy behaves as a trigger for undiagnosed essential thrombosis in this patient. She underwent anticoagulant therapy which still continuous. It seems that pregnancy became a triggering factor for ET in our case to show up with the symptoms like thrombosis. There is lack of evidence about duration of treatment. We don’t know when we should stop the anticoagulant therapy or we should continue the medications lifelong. This issue should be considered as the basis of future studies.},
year = {2021}
}
TY - JOUR T1 - Essential Thrombocytosis Detected in Pregnancy: A Case Report AU - Behshad Pazooki AU - Ailar Ahangari Y1 - 2021/12/24 PY - 2021 N1 - https://doi.org/10.11648/j.sjcm.20211004.21 DO - 10.11648/j.sjcm.20211004.21 T2 - Science Journal of Clinical Medicine JF - Science Journal of Clinical Medicine JO - Science Journal of Clinical Medicine SP - 143 EP - 146 PB - Science Publishing Group SN - 2327-2732 UR - https://doi.org/10.11648/j.sjcm.20211004.21 AB - Essential thrombocytosis is a myeloproliferative disease of unknown reason that causes progressive platelet overproduction, which this high counts of platelets appear to be associated with intravascular thrombosis and related event. There are several medications to prevent thrombosis formation in these patients, such as hydroxyurea, and aspirin. We do not have much information about the duration of the medication. Our case was a 28-year-old woman without any history of medical problem, who gave birth recently, presented to the emergency department with epigastric abdominal pain, nausea/vomiting, loss of appetite, chills and diarrhea. On initial examination, huge splenomegaly about 20 cm below the edge of the ribs in the midclavicular line were detected. All lab data were within normal ranges. Pregnancy behaves as a trigger for undiagnosed essential thrombosis in this patient. She underwent anticoagulant therapy which still continuous. It seems that pregnancy became a triggering factor for ET in our case to show up with the symptoms like thrombosis. There is lack of evidence about duration of treatment. We don’t know when we should stop the anticoagulant therapy or we should continue the medications lifelong. This issue should be considered as the basis of future studies. VL - 10 IS - 4 ER -
Email: